Drug Development
OTT excels in translating scientific discoveries into viable cancer therapeutics. We navigate the complex drug development process, optimising efficacy, safety, and commercial potential for breakthrough cancer medicines.
Oxford Target Therapeutics (OTT) is a pioneering pharmaceutical company focused on advancing innovative cancer therapies. We specialise in identifying and developing novel drug candidates that target crucial cellular processes involved in cancer progression. Our mission is to bridge the gap between cutting-edge research and transformative cancer treatments, empowering hope for patients facing this challenging disease.
OTT excels in translating scientific discoveries into viable cancer therapeutics. We navigate the complex drug development process, optimising efficacy, safety, and commercial potential for breakthrough cancer medicines.
OTT specialises in addressing unmet medical needs in oncology, with a key focus on difficult-to-treat cancers. Our mission is to develop novel solutions that bring hope to patients and improve their quality of life.
OTT is led and supported by a diverse team with complementary expertise from the medical sciences with long academic and industrial research experience as well as from the pharmaceutical industry and the capital markets.
Cutting-edge APC/C-targeting therapies with high potential for clinical success.
Targeting pressing unmet needs in oncology, offering hope and improved outcomes.
Exciting partnerships for accelerated drug development and widespread accessibility.
Oxford Target Therapeutics is committed to pushing the boundaries of innovation by fostering multidisciplinary research collaborations. We actively engage with leading companies, universities, and research institutions to leverage diverse expertise, capitalise on collaboration opportunities, and drive advancements in cancer drug development. Additionally, our strategic partnerships enable us to access specialised resources and capabilities through Contract Research Organizations (CROs), ensuring efficient and effective progress in our drug development programs.